We extend classical tumor regression models, such as the Norton-Simon hypothesis, from instantaneous regression rates (i.e. the derivative) to the cumulative effect (i.e. the integral) over one (or many) cycles of chemotherapy. To achieve this end, we use a stochastic Moran process model of tumor cell kinetics, coupled with a prisoner's dilemma game-theoretic cell-cell interaction model to design chemotherapeutic strategies tailored to different tumor growth characteristics. Using the Shannon entropy as a novel tool to quantify the success of dosing strategies, we contrast maximum tolerated dose (MTD) strategies as compared with low dose, high density metronomic strategies (LDM) for tumors with different growth rates.
Here, (w H , w C ) are "selection strength" parameters, 0 ≤ w H ≤ 1, 0 ≤ w C ≤ 1, that measure the strength of selection pressure on each of the population of cells. If w H = 0, there is no natural selection acting on the healthy cell population, and the dynamics is driven purely by the Moran process (i.e. random drift). When w H = 1, the selection pressure on the healthy cell population is strongest, and the prisoners dilemma payoff matrix has maximum effect.
From these formulas, we can define the transition probability of going from i to i + 1 cancer cells on a given step (P i,i+1 ) or from i to i − 1 on a given step (P i,i−1 ).
The first term in each each equation represents the probability that a cell is selected for reproduction (weighted by fitness). The second term represents the probability that a cell is selected for death. The probability of the number of cancer cells remaining the same (P i,i ) is given by the following. There are two absorbing states (P 0,0 , P N,N ). P i,i = 1 − P i,i+1 − P i,i−1 ; P 0,0 = 1; P N,N = 1 (5) 1 Introduction
Low dose metronomic chemotherapy (LDM) is the systematic and frequent delivery of chemotherapeutic agents at doses lower than the maximum tolerated dose paradigm (MTD) (3, 4) . It is typically given at a low dose between 1/10th and 1/3rd of the maximum tolerated dose, without a long period of time between subsequent doses, hence it is also associated with higher dose densities (3) . Important features of low dose, high density metronomic chemotherapy include: regular administration of chemotherapy without any interruptions using an optimized dose; preference for oral drugs; low incidence of side effects; low risk of developing resistance; lower cost. In addition, some elderly or frail patients may only be suited for lower dose chemotherapy. Residual toxicity from previous treatment may also reduce consideration for MTD chemotherapy (4) . Metronomic chemotherapy regimens have been associated with lower cost of inexpensive oral drugs such as cyclophosphamide and result in fewer side-effect associated expenditures. Several phase II studies have shown promises of metronomic-like chemotherapy and its excellent safety profiles (4) . The lower doses of metronomic chemotherapy regimens are now thought to not only reduce the harmful side effects of toxicity delivered to the patient but perhaps also improve anti-tumor effects (5) , by killing endothelial cells in addition to its cytotoxic effect on cancer cells (6, 7) in an uninterrupted schedule for prolonged treatment periods. Metronomic chemotherapy has been shown to be effective in preclinical trials where cancer cells have developed resistance to the same chemotherapeutics (5) . These LDM regimens are also suited to combination or additive strategies to new targeted and relatively non-toxic anticancer drugs recently developed.
While the advantages of LDM chemotherapy may be wide ranging with respect to toxicity, resistance, and anti-angiogenic effects (outside of the scope of our model), the goal of this article is to use an evolutionary mathematical model of cell/tumor growth with the abil- For a low dose metronomic chemotherapy, any schedule that administers a lower dose at more frequent intervals (higher dose density) could be classified as "low dose metronomic."
But, as seen above, in clinical practice the relative dose intensity delivered and the density of the scheduled are varied without clear consensus. In fact, only one monotherapy treatment regimen kept the RDI constant, balancing the lower dose with an equivalent increase in dose density. Of the remaining 23 regimens about half increased RDI (n = 12) while half decreased RDI (n = 11). It is evident that many of the quantitative details of LDM chemotherapy are unresolved including patient selection, choice of drug (or combinations of drugs and treatments), and optimal dose and treatment intervals (4) . With this in mind, the goal of this manuscript is very targeted. We wish to quantify the relationship between dose and dose density delivered using the Shannon entropy index (8) as a quantitative scheduling and dosage tool. We will first briefly review the prisoner's dilemma evolutionary game theory model of primary tumor growth that we use to carry out our computational trials (9, 10) as well as the notion of Shannon Entropy as an index to compare chemotherapeutic regimens in order to show that high entropy schedules (with an adequate dose intensity) outperform low entropy schedules.
The classic tumor regression laws
Benzekry et al. (11) chronicle that, despite a rise in personalized and precision medicine, currently chemotherapeutic agents are often still administered in the maximum tolerated dose paradigm. The author predicts that the forthcoming development of metronomic chemotherapy may pave the way for implementing "computational oncology at bedside, because optimizing metronomic regimen should only be achieved thanks for modeling support." This prediction characterizes a growing field sometimes referred to as computational or mathematical 7 oncology (12, 13) . First, however, in order to properly understand how alternative dosing schedules like the metronomic regimens fit into the future of chemotherapy scheduling, it is important to remember the reasons that led to the advent and continued use of MTD paradigms.
Skippers Laws
The relationship between dose and tumor cytotoxicity is linear-log (i.e. exponential decay) (14) . Skipper et al. (15) were the first to develop a set of theoretical laws governing the behavior (and imply the design) of chemotherapy schedules in cancer in the late 1970s. Our understanding of the Gompertzian growth of tumors have made the application of these laws more complex, but the fundamentals of these laws still apply today (16) .
In a tumor that grows exponentially (eqn. 6 and 7) with a constant exponential rate, the first law states that the tumor volume doubling time is constant over the life of the tumor
n(t) = n 0 exp(αt)
The second of Skipper's laws is that the percentage of cells killed by a given drug dose, D, is constant, therefore a linear increase in dose causes a log increase in cell kill (13) . As an example, a drug dose, x, that shrinks tumor size from 10 6 to 10 5 cells results in a 90% decrease of tumor population. An identical subsequent drug dose (a total dose of 2x) will further reduce tumor population size according to that same kill constant, to corresponding to the instantaneous growth rate (γ(t)). Gompertzian growth is given by the following coupled ordinary differential equations.
The Gompertz function reduces to the exponential function when α = 0. These coupled ordinary differential equations may be directly solved, as follows.
The Norton-Simon hypothesis states that tumor regression is positively (linearly) correlated with the instantaneous growth rate just before the treatment of the unperturbed tumor (17, 18) . Generally, smaller tumors are associated with higher growth rates (and therefore, higher regression rates). Mathematically, the Norton-Simon Hypothesis can be formulated,
where n(t) is the growth rate model of the tumor at time t, f (n(t)) is the growth dynamics associated with the unperturbed tumor (i.e. exponential growth or Gompertzian growth), and L(t) is the loss function of cells resulting from treatment. The growth function f (n(t)) may be assumed to be exponential, (eqn. 7) or Gompertzian, (eqn. 9 and 10). Remembering that Skippers second law states that cell kill follows first-order kinetics, we may assume for the time being that L(t) ≡ const., or that the rate of cell removal due to treatment is constant. In other words, each dose of chemotherapy is associated with some value of L.
The goal is to find the optimal dose concentration and dose density that maximize the loss rate of cell kill, L.
The Implications of the Norton-Simon Hypothesis
Norton and Simon hypothesized that chemotherapy will only be effective in targeting cells that are in active proliferation (and as such are directly contributing the growth of the tumor in equation 12). Their model demonstrated ability to fit data preclinical experiments (19) and predict future tumor growth and regression after a few initial measurements and data from clinical trials in breast cancer (18) .
The model has several key implications. First, the model predicts a higher regression for higher dose delivered. The highest dose tolerable to the patient should be chosen. Second, tumor regrowth during rest periods of chemotherapy necessitates a shorter rest period and subsequently, a shorter time of tumor regrowth. The next round of a dose dense chemotherapy will attack a smaller tumor (with higher growth rate) and lead to higher regression. Both implications give rise to the invention of the MTD paradigm to attack the tumor with the highest dose, coupled with shortest rest. These predictions were confirmed by clinical trials in which chemotherapy schedules were densified from 21 to 14 days (20) . The hypothesis also 10 predicts that tumors with an identical tumor burden may have varied responses.The growth rate of the tumor determines the response to chemotherapy. As such, early administration is important, implying a better response when the tumor is in initial stages of high growth.
Similar models using the ratio of tumor volume to the host-influenced tumor carrying capacity (which corresponds inversely to the instantaneous growth rate of the tumor) has been shown to inversely predict radiotherapy response (21) .
Fundamentally however, the Norton-Simon hypothesis provides no predictions for the effect of dose and dose density on regression. The Norton-Simon hypothesis (equation 12) conceals the fact that the rate of cell-kill, L(t) will be dependent on two factors: drug concentration and the number of days the drug is administered. The goal of this manuscript is to extend the classical and well-accepted predictions of Norton-Simon hypothesis from instantaneous regression rates (i.e. the derivative) to the cumulative effect (i.e. the integral) over one (or many) cycles of chemotherapy. Chemotherapy "strategies," or schedules are quantified using the Shannon entropy (8) by their total cell reduction (TCR) over the course of the full schedule, rather than the initial regression rate (β). The evolutionary model we introduce in this paper is compared with regression data from murine models (see figure 3 ) and shown to be in good agreement.
2 Materials and methods
Chemotherapeutic agents alter the fitness landscape
It is now well established that cancer is an evolutionary and ecological process (22, 23) .
Studying cancer as a disease of clonal evolution has major implications on tumor progression, prevention and therapy (24, 25) . The evolutionary forces at play inside the tumor such as genetic drift with heritable mutations and natural selection operating on a fitness landscape are influenced by tumor microenvironment and the interactions between competing cell types.
Increased selection will influence the rates of proliferation and survival, which cause the population of cells within a tumor to progress toward more invasive, metastatic, therapeutic resistant cell types. The role of chemotheraputic agents is to kill proliferating cancer cells.
This effect can be viewed as a change in fitness landscape (altering the evolutionary trajectory of the tumor), which we model as a change in the selection pressure, explained in more detail below.
In order to model these complex evolutionary forces in cancer, many theoretical biologists have used an evolutionary game theory (EGT) framework, pioneered by Nowak, to study cancer progression (see (26, 27, 28, 1, 29) ). Evolutionary game theory provides a quantitative framework for analyzing contests (competition) between various species in a population (via the association of strategies with birth/death rates and relative sub-clonal populations) and
provides mathematical tools to predict the prevalence of each species over time based on the strategies (30, 31, 28, 32) . More specifically, the framework of EGT allows the modeler to track the relative frequencies of competing subpopulations with different traits within a bigger population by defining mutual payoffs among pairs within the group. From this, one can then define a fitness landscape over which the subpopulations evolve.
The model
The model presented in (9, 10) and used in this paper to carry out our computational trials is a framework of primary tumor growth used to test the effect of various chemotherapuetic regimens, including MTD and LDM. The model is a stochastic Moran (finite-population birth-death) process (33) that drives tumor growth, with heritable mutations (34) operating over a fitness landscape so that natural selection can play out over many cell division timescales (described in more detail in (9, 10) ). The birth-death replacement process is based on a fitness landscape function defined in terms of stochastic interactions with payoffs determined by the prisoner's dilemma game (1, 2) . This game incorporates two general classes of cells: healthy (the cooperators) and cancerous (the defectors) (35, 36) . During tumor progression, each cell is binned into one of two fitness levels, corresponding to their proliferative potential: healthy (low fitness) and cancer (high fitness). In our model, we can think of a cancer cell as a formerly cooperating healthy cell that has defected and begins to compete against the surrounding population of healthy cells for resources and reproductive prowess.
The model demonstrates several simulated emergent 'cancer-like' features: Gompertzian tumor growth driven by heterogeneity (37, 38, 39) , the log-kill law which (linearly) relates therapeutic dose density to the (log) probability of cancer cell survival, and the Norton-Simon hypothesis which (linearly) relates tumor regression rates to tumor growth rates, and intratumor molecular heterogeneity as a driver of tumor growth (10) . Others have presented mathematical models to study evolutionary dynamics of tumor 13 response to targeted therapy (40) in either combination or sequential therapy (41, 42) , and optimal drug dosing schedules to prevent or delay the emergence of resistance or optimize tumor response (43, 44, 45) . We are interested testing "strategies, strong selection. We break w into two separate parameters, w H , the selection pressure on the healthy population, and w C , the selection pressure on the cancer population (see figure   1a ). Each dose of chemotherapy is associated with a dose concentration, c, which alters the selection pressure as indicated in figure 1a . Here, we assume drug concentration will be measured as as a fraction of the conventional maximum tolerated dose (MTD) dosages, hence 0 ≤ c ≤ 1 (see Figure 1b ). As c increases, the selection pressure is altered in favor of the healthy cells (w H > w) and to the detriment of cancer cells (w C < w) as shown in Figure 1a . Before therapy, the fitness landscape of an untreated tumor is that of a prisoner's dilemma (Figure 1c) , where the fitness of the cancer subpopulation is greater than the healthy population for the entire range of cancer proportion, i/N . The change in fitness landscape for a moderate value of c (c = 0.4) is shown in Figure 1d , which gives the healthy cell population a fitness advantage over the cancer population. The advantage is lessened as the tumor size (i/N ) increases (which contributes to the emergence of the Norton-Simon model in Figure 2 , explained in detail below). For a strong dose of therapy (such as c = 0.8, shown
in Figure 1e ), the effect on the fitness landscape is exaggerated. Thus, a higher dose leads to a higher kill rate of cancer cells.
In literature, two models have been proposed to model loss functions due to a drug: 
Dose concentration versus dose density
Despite a growing trend toward personalized and precision medicine, treatment goals have shifted from complete cure to an optimization of long term management of the disease; rather than trying to find the silver bullet, we might utilize the advances in mathematical models to optimize existing therapeutic options (11, 48) . For this reason, we have decided to test the merit of various chemotherapeutic regimens by comparing the total tumor cell reduction (TCR). Presumably, a therapy regimen with a higher value of TCR will provide a greater level of tumor control, a longer time to relapse, and better prognosis. represents the percentage of days a dose is administered. In order to compare the importance of each term on tumor cell reduction, we hold one term constant and vary the other in Figure   4 .
Clearly seen in Figure 4a , there is a diminishing return on increasing the dose strength of a given chemotherapy regimen. Although there is a positive relationship (an increase in dose leads to a higher regression) that relationship lessens as the dose is increased further.
However, in Figure 4b , the relationship between dose density and regression is linear, showing no signs of diminishing returns of increasing density.
The point has an important subtlety: the dose cannot be continually lowered in favor of density. The dose must be sufficient to overcome the growth rate of the tumor; some doses are not adequate for tumor regression regardless of the density. This is seen for values below the dotted line in Figure 4a and 4b.
Results

Quantifying chemotherapeutic strategies via entropy metric
In clinical practice today, there are three common chemotherapy regimens in use considered here: Maximum Tolerated Dose (MTD), Low Dose Metronomic weekly (LDMw) and Low Dose Metronomic daily (LDMd). These three chemotherapy strategies are shown in Figure 5 , left. Each regimen consists of identical cycles that are repeated until the tumor is eradicated.
The MTD (left, top) regimen delivers the maximum dose on a single day, repeated once every There are hundreds of such choices of chemotherapy regimens when considering varying doses across many days or weeks ( Figure 5, right) , each varying the total dose delivered, D, and the density, d. We propose using a Shannon Entropy index, E, of a given chemotherapy schedule as a measure that can quantify and synthesize information of both the dose on a given day and the distribution of unique, daily doses across the entire chemotherapy regimen into a single metric. The entropy is calculated as follows, where c i is the dose strength (often simply referred to as 'dose') on day i. 20
The assumption in equation 13 that an identical dose is delivered every day can be relaxed, and the total dose delivered is found by summing the dose on each ith day (c i ) multiplied by the length of the dose in days (t i ). We assume that the smallest resolution of discrete times between doses, t i is a single day, or t i = 1 for all i. N is the number of days between cycles, also known as the intercycle time.
The dose density of a regimen can be found by summing the number of days where a non-zero dose is delivered, and dividing by the intercycle time in days, N . Thus, the density will be a non-dimensionalized parameter such that (0 ≤ d ≤ 1).
The Shannon entropy metric, E, is an ideal metric for comparing chemotherapy regimens because it separates the existing cases already in clinical practice today: MTD (low entropy, characterized by high doses with long periods of rest), metronomic regimens (high entropy,
characterized by low doses with short or no periods of rest), as well as any arbitrary strategy of varied doses administered in a cycle of arbitrary length of days. All of the simulated therapy regimens were assumed to be frontloaded (non-increasing, with the highest dose on day 1 and equal or lower subsequent doses). Backloaded regimens give similar but slightly disadvantageous results, because backloaded regimens often start with a period of rest, giving the tumor time to grow to a larger tumor, which is associated with a lower growth rate (and therefore lower regression). 21 
LDM versus MTD chemotherapies
Computational simulations of 1000 unique chemotherapy schedules were run with identical initial conditions (N = 1e6 cells; i/N = 1e3). Mean values of tumor cell regression percentage for 50 simulations were calculated and plotted in a pictorial histogram according to regression percentage ( Figure 6 ). Both slow growing tumors (w = 0.1) and fast growing tumors (w = 0.2) were simulated.
Each block represents a chemotherapy regimen, which has an associated Shannon en- In Figure 7 , the analysis is repeated for varied tumor growth rates (i.e. varied selection pressure) for w = 0.1, (blue) w = 0.2, (red) and w = 0.3 (yellow). The difference in reduction is shown for 1 cycle, 8 cycles, and 16 cycles. Fast growing tumors have a high slope on a least-squares linear fit approximation of the entropy-TCR plot, which means that high entropy therapies (LDM) are more effective for fast growing tumors than for slow growing tumors. By contrast, slow growing tumors have a lower slope on the entropy-regression plot, which means that all regimens have relatively similar performance outcomes. Fast growing tumors, therefore, have a higher likelihood of benefiting from a more LDM-like chemotherapy, provided the dose is adequate to lead to tumor regression. The effect is almost negligible after a single cycle (Figure 7a ). The appeal of the implication of Norton-Simon toward an MTD approach to chemotherapy lies in the high initial response of tumors to a high dose. The metronomic chemotherapies take more cycles to overtake the initial quick response of the MTD, but after the 8 cycles ( Fig. 7b ) and 16 cycles ( Fig. 7c) , the cumulative effect is evident and metronomic chemotherapies outperform MTD therapies. For each growth rate (i.e. selection pressure), there is a corresponding optimal chemotherapy schedule. In each case, the optimal solution corresponds to the highest entropy (which corresponds to the low-dose metronomic chemotherapy schedule). (c) Figure 7 : High entropy strategies lead to an increase in tumor regression -The relationship between tumor cell reduction (TCR) and entropy (H) is shown for a single cycle of chemotherapy (a), 8 cycles (b), and 16 cycles (c). The simulations (averages of 25 stochastic simulations for total dose delivered D = 0.3) are repeated for slow (w = 0.1, blue), medium (w = 0.2, red), and fast growing tumors (w = 0.3, yellow). The low slope value in (a) indicates negligible advantage of high entropy strategies after only a single cycle. After many cycles, the advantage of high entropy strategies is apparent (b,c). Also note that the slope associated with faster growing tumors (yellow) is higher than those of slower growing tumors (blue). This indicates that at high entropies, TCR for the fast growing tumors is closer to those for slow growing tumors, as compared with low entropies.
Discussion
We use a stochastic Moran process model coupled with a prisoner's dilemma evolutionary game (cellular interactions) to contrast LDM and MTD chemotherapies with respect to 24 their effect on tumor growth. The Shannon entropy was identified as a useful metric to compare chemotherapy strategies. The metric is useful in quantifying LDM strategies (which correspond to high entropy values), MTD strategies (low entropy), as well as novel strategies with intermediate entropy values.
Our results show that high dose chemotherapy strategies outperform low dose, although there are some subtleties associated with the growth rates of the tumors. Dosing consists of a product of concentration and density and our results show that an increase in density is more effective than the same percentage increase in concentration. In other words, higher dose concentrations shown diminishing returns. The effectiveness of density in leading to a higher tumor cell reduction allows the LDM chemotherapies (which are more dose dense)
to outperform MTD strategies. This effect is magnified for fast growing tumors that thrive on long periods of unhindered growth without chemotherapy drugs present. This effect is not evident after a single cycle of chemotherapy, but is magnified after each subsequent cycle of repeated chemotherapy. We could ask if there is any evidence of this effect in the literature on clinical trials already performed. We first point to a paper comparing different chemotherapeutic schedules for prostate tumors (49) (relatively slow-growth rates). In this phase 3 study, docetaxel dosing given every three weeks was compared to dosing every week.
The mean survival was only slightly higher for the first group (three weeks) compared with the second (weekly), showing no obvious benefit to a low-dose high density treatment. By contrast, a phase 2 trial for small cell lung cancer (SCLC) (50) was performed, a tumor with typically higher growth rates than prostate tumors. For this group, the drug topotecan was administered on a higher dose weekly basis with disappointing results, pointing out the advantages of the LDM therapies for this fast-growing tumor type.
Thus our model points to the benefits of choosing dosing strategies based on tumor growth rates, something not currently done in medical practice. The concept of choosing dosing schedules based on tumor growth rates could well be a fruitful avenue to test further in clinical trials focused on this question. Others have attempted to estimate prospective patient-specific tumor growth rates to make clinical decisions about treatment scheduling and fractionization, using measurements at diagnosis and first day of treatment (51, 21) .
Furthermore, the promise of LDM chemotherapy on mitigating the risk of resistance (5) and metastasis (11) could be a separate line of future investigation.
